
|Videos|July 22, 2021
Vyluma pipeline focuses on refractive error
Advertisement
Vyluma, which recently spun off from Nevakar, has a robust pipeline for potential therapies addressing refractive error. Navneet Puri, PhD, the company’s founder, chairman, and CEO, offers additional insights.
Newsletter
Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Optometry Times - Clinical News & Expert Optometrist Insights
1
2025 takes dry eye, presbyopia by storm
2
Systematic review finds driving negatively impacted by glaucomatous VF defects
3
BLA accepted, priority review granted by US FDA for Viridian Viridian Therapeutics’ veligrotug
4
Adopting Emerging Therapies in Dry Eye Care
5












































